Roth Capital Remains Positive on Regeneron (REGN); Latest Outcome Better Positions Eylea as Superior DME Treatment
Tweet Send to a Friend
Roth Capital affirms Regeneron Pharma (Nasdaq: REGN) at Buy with a price target of $422 following news that the NIH-sponsored ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
